The Committee for Veterinary Medicinal Products (CVMP), at its meeting on 2-4 December 2025, adopted a favourable opinion on the marketing authorisation of Varenzin (molidustat) from Elanco GmbH.1[2][3] The drug is intended for the treatment of non-regenerative anaemia associated with chronic kidney disease (CKD) in cats by increasing the haematocrit.[1][3] Molidustat acts as a HIF-PH inhibitor, which stimulates the production of endogenous erythropoietin and promotes erythropoiesis.[3] The most common side effect is vomiting.3][3] The CVMP also approved changing the frequency of the adverse reaction "application site reaction" for Felpreva (meloxicam) from very rare to rare.[1] Other positive opinions concerned changes to the product information for Mirataz and manufacturing quality changes for products such as AdTab, Dexdomitor, Duotic/Osurnia, Eluracat, Meloxidyl, Nexgard, ProteqFlu-Te, Sileo and Zuprevo.The Committee was informed of the withdrawal of the Marketing Authorisation Application for Livencia from Vetbiobank.[1]